Liver Cancer Lab

We are a liver cancer and regeneration research group at Hannover Medical School
AG-Vogel/AG-Saborowski @ArndtVogel @SaborowskiAnna

[Arndt Vogel @ArndtVogel]

Good morning Barcelona!

Looking forward to day second of #WCGIC2022

Starting off with challenging #HCC cases with @DucreuxMichel @GABOUALFA Bruno Sangro Rene Adams and Thierry de Baere

[Arndt Vogel @ArndtVogel]

New #immunotherapy kids on the block for advanced #CRC?

Very promising data presented #WCGCI2022

Botensilimab and Balstilimab —> Fc enhanced CTLA4/PD1 combination

Compelling ORR of 24%
Is there a role of liver mets for IO efficacy?

@myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

Looking forward to a great symposium on #PrecisionMedicine in #cholangiocarcinoma

👉join us 13:00 at #WCGIC2022 to discuss targeted therapies with #JohnBridgewater #EricvanCutsem @LorenzaRimassa

@myESMO @enscca

[Anna Saborowski @SaborowskiAnna]

Super proud of my colleague @ArndtVogel for presenting the final analysis of the practice changing Fight-202 trial for pts with FGFR2 altered #cholangiocarcinoma at #WCGIC2022 #livertwitter

[Vivek Subbiah, MD @VivekSubbiah]

⭐️#BRAF #TissueAgnostic #PrecisionMedicine @OncoAlert

[Arndt Vogel @ArndtVogel]

👏Comprehensive review on BRAF V600E
doi: 10.1158/1535-7163.MCT-21-0950

👉detected in > 40 cancer types
👉BRAF inhibition effective > 20 cancer types
👉RWD in 69 cancer types
👉BRAFi/MEKi > BRAFi , but CRC + EGFRi
👉9 FDA approvals, now tumor-agnostic

@OncoAlert @myESMO

[Arndt Vogel @ArndtVogel]

👏Understanding evolution of resistance to targeted therapy
https://t.co/cXXNuXPJal.

❓selection or de novo acquisition?
👉CaTCH: method to analyze founder clones their postselection counterparts

Proof of concept for RAFi/MEKi resistance

#precisionmedicine

[ESMO - Eur. Oncology @myESMO]

#WCGIC2022 #Youngoncologist sessions: 'ESMO Session: Focus on Young Oncologists, with #ESMOYOC', plus finding local & intl. mentors to build your career, #Gendermedicine in #GItumours, disparities in access to new drugs 👇
🔗 https://t.co/AEXAuRLuco
@ESMOWorldGI #GIcancer

[Arndt Vogel @ArndtVogel]

💊💊Critical appraisal of FDA approvals: food for thoughts!
https://t.co/drFkFA0NKF

👉 71 2002-14
👉161 2017-21
👉71 IO 💉
👉 62 small molecules💊
👉 5 T-agnostic

✅ 47 with OS
❗️ 58 with ORR
❗️ 39 with PFS

❗️only 42 with subs. benefit acc.ESMO-MCBS

@myESMO #Immunotherapy

[Arndt Vogel @ArndtVogel]

Great day to start ESMO-Gi in Barcelona

[Anna Saborowski @SaborowskiAnna]

Watch on demand: today's tumor heterogeneity symposium #ILC2022 with @Valeriechew29 from 🇸🇬:
⬆️immune intratumoral heterogeneity is associated with
⬆️immunosuppressive tumor microenvironment and
⬇️clinical outcome parameters in #HCC
👉https://t.co/FxIbMecQlm
#LiverTwitter

[Anna Saborowski @SaborowskiAnna]

EASL YI task force preparing for the YI Seminar tomorrow at 08:00 sharp😀. Make sure to join us there, early birds 🦆 @EASLedu #LiverTwitter #ILC2022

[Anna Saborowski @SaborowskiAnna]

Hurry up or you will miss Heiner Wedemeyer‘s Talk in the YI Symposium ! Capital Suite 17! Now! No excuses! #ILC2022

[Anna Saborowski @SaborowskiAnna]

Entertaining and informative talk by H. Wedemeyer
➡️history of discoveries of hepatitis viruses
➡️landmark publications and their
➡️impact on hepatitis treatment strategies
A grand start to the YI Symposium ⭐️(And I am NOT saying this bc he is my boss…)

[Anna Saborowski @SaborowskiAnna]

This is EXACTLY what we aimed for when preparing the yi symposium: excellent speakers that take us on a journey 🧭through their field, highlighting novel developments but also dead ends. Thank you @analleo for your insights and advice!#ILC2022 #LiverTwitter

[Anna Saborowski @SaborowskiAnna]

Future of metabol. liver disease research: key insights from M. Vacca:
❗️Stop using 2D cultures for metabolic studies, go for precision cut liver slices
❗️multi organ on chip and
❗️advanced natural ecm organoids is what we should aim for
‼️Consensus on preclin. models are key!

[Arndt Vogel @ArndtVogel]

��FGFR2 alterations in #cholangiocarcinoma

👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2
👉rearrangement: gene is out-of-frame with ex. 17
👉truncation: loss of neg. regulatory element
👉In-Frame Deletion..

✅all druggable
@myESMO

[Arndt Vogel @ArndtVogel]

🔥concerning data on acetaminophen for #immunotherapy @JCO_ASCO
https://t.co/3HGRQ4NjXp

👉APAP --> Treg⬆️ --> IO efficacy⬇️: ORR, PFS, OS

❗️be aware of concomitant💊💊:statins, steroids, antibiotics, proton-pump inhibitors...

@OncoAlert @myESMO

[Arndt Vogel @ArndtVogel]

👏Excellent summary on Hyperprogression and #Immunotherapy in @trendscancer
https://t.co/dN8gY8qgWz

👉no clear definition, only retros. data
👉no biomarker
❓role of TME

✅clear need to identify patients with devastating outcome on ICI

@OncoAlert, @myESMO

[Anna Saborowski @SaborowskiAnna]

YI Paula Olaizola presenting her comprehensive work on the role of NEDDylation in #cholangiocarcinoma in the abstract session
➡️targeting NEDDylation pharmacologically or genetically impacts tumor growth in vitro & in vivo
👏to new takes on CCA!
#LiverTwitter #ILC2022